MXPA03003589A - Tratamiento de adiccion a pcp y comportamiento relacionado con adccion a pcf. - Google Patents

Tratamiento de adiccion a pcp y comportamiento relacionado con adccion a pcf.

Info

Publication number
MXPA03003589A
MXPA03003589A MXPA03003589A MXPA03003589A MXPA03003589A MX PA03003589 A MXPA03003589 A MX PA03003589A MX PA03003589 A MXPA03003589 A MX PA03003589A MX PA03003589 A MXPA03003589 A MX PA03003589A MX PA03003589 A MXPA03003589 A MX PA03003589A
Authority
MX
Mexico
Prior art keywords
pcp
mammal
addiction
amount
administered
Prior art date
Application number
MXPA03003589A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan D Brodie
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of MXPA03003589A publication Critical patent/MXPA03003589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MXPA03003589A 2000-10-23 2001-03-07 Tratamiento de adiccion a pcp y comportamiento relacionado con adccion a pcf. MXPA03003589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/694,040 US6395783B1 (en) 2000-10-23 2000-10-23 Treatment of PCP addiction and PCP addiction-related behavior
PCT/US2001/007233 WO2002034249A1 (en) 2000-10-23 2001-03-07 Treatment of pcp addiction and pcp addiction-related behavior

Publications (1)

Publication Number Publication Date
MXPA03003589A true MXPA03003589A (es) 2005-08-16

Family

ID=24787164

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003589A MXPA03003589A (es) 2000-10-23 2001-03-07 Tratamiento de adiccion a pcp y comportamiento relacionado con adccion a pcf.

Country Status (17)

Country Link
US (1) US6395783B1 (https=)
EP (1) EP1335717A4 (https=)
JP (1) JP2004512301A (https=)
KR (1) KR20030074610A (https=)
CN (2) CN1234352C (https=)
AU (2) AU4201101A (https=)
BR (1) BR0114898A (https=)
CA (1) CA2426210C (https=)
CZ (1) CZ20031431A3 (https=)
HR (1) HRP20030322A2 (https=)
HU (1) HUP0301441A3 (https=)
IL (2) IL155574A0 (https=)
MX (1) MXPA03003589A (https=)
NO (1) NO20031814L (https=)
NZ (1) NZ526072A (https=)
PL (1) PL361028A1 (https=)
WO (1) WO2002034249A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN114903006B (zh) * 2021-02-09 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物物质成瘾模型的构建方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2133002B (en) 1982-12-30 1986-01-29 Merrell Toraude & Co Process for preparing 4-amino-5-hexenoic acid
GB8311804D0 (en) 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
JPH03500411A (ja) 1987-10-07 1991-01-31 マトリックス　テクノロジーズ　インコーポレーテッド コカイン中毒の処置および治療薬
US5102913A (en) * 1991-07-01 1992-04-07 Halikas James A Treatment for cocaine use employing valproic acid
KR20010031470A (ko) 1997-10-28 2001-04-16 둘락 노먼 씨. 포유동물의 갈망을 감소시키는 방법
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
CN100548290C (zh) 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途

Also Published As

Publication number Publication date
JP2004512301A (ja) 2004-04-22
WO2002034249A1 (en) 2002-05-02
IL155574A0 (en) 2003-11-23
CN1476326A (zh) 2004-02-18
KR20030074610A (ko) 2003-09-19
CZ20031431A3 (cs) 2004-06-16
HUP0301441A3 (en) 2011-07-28
AU2001242011B2 (en) 2005-11-03
BR0114898A (pt) 2003-08-12
NZ526072A (en) 2004-08-27
CN1234352C (zh) 2006-01-04
CA2426210C (en) 2009-12-22
CN1771929A (zh) 2006-05-17
PL361028A1 (en) 2004-09-20
CA2426210A1 (en) 2002-05-02
HRP20030322A2 (en) 2005-02-28
NO20031814L (no) 2003-06-19
EP1335717A1 (en) 2003-08-20
AU4201101A (en) 2002-05-06
EP1335717A4 (en) 2004-06-30
AU2001242011B8 (en) 2006-03-02
HUP0301441A2 (hu) 2003-11-28
US6395783B1 (en) 2002-05-28
IL155574A (en) 2010-02-17
NO20031814D0 (no) 2003-04-23

Similar Documents

Publication Publication Date Title
CA2339192C (en) Treatment of addiction and addiction-related behavior
Gamberino et al. Neurobiology of tobacco smoking and other addictive disorders
London et al. Effects of L-cocaine on local cerebral glucose utilization in the rat
Glimcher et al. Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain.
Wilcox et al. Self‐administration of cocaine and the cocaine analog RTI‐113: Relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys
US20020042446A1 (en) Treatment of addiction and addiction-related behavior
US6828349B1 (en) Treatment of addiction and addiction-related behavior
Wilkerson et al. Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat
US6395783B1 (en) Treatment of PCP addiction and PCP addiction-related behavior
Casey et al. Effect of des-tyrosine-γ-endorphin in tardive dyskinesia
AU2001242011A1 (en) Treatment of PCP addiction and PCP addiction-related behavior
Ginsburg et al. Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys
Sanchez et al. Prevention by sodium 4, 5-dihydroxybenzene1, 3-disulfonate (tiron) of vanadium-induced behavioral toxicity in rats
Weissman et al. Effects of self-administered phencyclidine on regional uptake of 2-deoxy-D-[1-14C] glucose in brain
Steketee Repeated injection of GBR 12909, but not cocaine or WIN 35,065-2, into the ventral tegmental area induces behavioral sensitization
Lux et al. Studies on the mechanism of hypoglycemia induced by intrathecal morphine: dissociation from behavioral effects, effects of tolerance and depletion of liver glycogen.
Stennett Novel Therapy for Nicotine Addiction in Alcohol Dependent Rats
Irizarry et al. Substance dependence as a compulsive behavior George F. Koob, M. Rocio, A. Carrera, Lisa H. Gold, Charles J. Heyser, Carmen Maldonado
KR20010085332A (ko) 중독 및 중독 관련 행동의 치료

Legal Events

Date Code Title Description
FG Grant or registration